Doctoral Study Program of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia; School of Pharmacy, Universitas Muhammadiyah Yogyakarta, Yogyakarta, Indonesia.
Department of Pharmacology and Clinical Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Value Health Reg Issues. 2021 May;24:12-16. doi: 10.1016/j.vhri.2020.05.010. Epub 2021 Jan 16.
In Indonesia, no study has been published to evaluate the utility scores among children with pneumonia. This study aims to quantify the health-related quality of life (HRQOL) of children with pneumonia in Indonesia using the EuroQoL Descriptive System (EQ-5D-5L) value set for Indonesia.
A hospital-based cross-sectional survey was conducted between September 2017 and March 2018. Children aged <14 years old who were hospitalized for pneumonia in 11 hospitals in Yogyakarta were recruited for this study. The EQ-5D-5L and visual analogue scale (EQ-VAS) were applied to the parents (proxy-assessment).
A total of 384 patients were hospitalized with pneumonia. Among those patients, 338 (88.02%) were without congenital diseases; and 46 (11.98%) were with congenital diseases. The mean of utility scores in all patients was 0.67 ± 0.28, while the mean of visual analog scale (VAS) score was 67.66 ± 21.98. The mean of utility scores and VAS scores decreased among those with congenital diseases, which is 0.51 ± 0.51 and 65.41 ± 19.42, respectively. However, the utility score and VAS scores among patients without congenital diseases were higher than the category of all patients. Showing the number of,0.69 ± 0.23 and 68.0 ± 22.3, respectively.
This study confirmed that children with pneumonia had a negative impact on HRQOL. The HRQOL could be used for future economic evaluation studies.
在印度尼西亚，尚无研究评估肺炎患儿的效用评分。本研究旨在使用印度尼西亚的 EuroQoL 描述性系统（EQ-5D-5L）效用值集，量化印度尼西亚肺炎患儿的健康相关生活质量（HRQOL）。
本研究采用医院横断面调查，于 2017 年 9 月至 2018 年 3 月期间在雅加达的 11 家医院进行。共招募了 384 名因肺炎住院的<14 岁儿童。父母（代理评估）应用 EQ-5D-5L 和视觉模拟量表（EQ-VAS）。
共有 384 名患者因肺炎住院。其中，338 名（88.02%）无先天性疾病，46 名（11.98%）有先天性疾病。所有患者的效用评分平均值为 0.67±0.28，而视觉模拟量表（VAS）评分平均值为 67.66±21.98。患有先天性疾病的患者的效用评分和 VAS 评分均值均降低，分别为 0.51±0.51 和 65.41±19.42。然而，无先天性疾病的患者的效用评分和 VAS 评分高于所有患者。分别为 0.69±0.23 和 68.0±22.3。
本研究证实肺炎患儿的 HRQOL 受到负面影响。HRQOL 可用于未来的经济评估研究。
